Importancia de la polietilenimina en biomedicina y sus aplicaciones en terapia génica

  1. Margarita López-Viota Gallardo 1
  2. Raúl Megías Iglesias 1
  3. Mª. Adolfina Ruiz Martínez 1
  4. Jose Luis Arias Mediano 1
  1. 1 Universidad de Granada, España
Journal:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Year of publication: 2014

Volume: 55

Issue: 1

Pages: 50-58

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Ars pharmaceutica

Abstract

Therapy is a branch of health science that deals with the means used and the manner of application in the treatment of diseases in order to relieve symptoms or produce a cure. Today there are many therapeutic tools available to combat the diverse health problems faced daily. With this evolution of medicine, it is inevitable that more and better strategies emerge leading to a more innovative therapeutic spectrum. Within the new strategies, we find that gene therapy is currently one with most potential. This type of therapy is based on using genetic material as an active substance against various pathologies and it is on which this literary review is focused. With the high demand for systems that vehiculize genetic material, diverse forms of carrying said material have emerged in the past decade. One of these forms consists of the use of non-viral vectors. The non-viral vectors act as transfectants that evade problems inherent to the use of viral structures such as immunological reactions. Polyethylenimine has emerged as the most promising polymer in this field for many reasons which will be illustrated in this paper. The objectives of this review are to give the reader an understanding of what Polyethylenimine is, why it has produced so much interest today in gene therapy, and what its applications are, with special emphasis on cancer treatment.

Bibliographic References

  • Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed Nanotechn Biol Med. 2013;9(1):1-14.
  • Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008;126(3):187-204.
  • Webster DM, Sundaram P, Byrne ME. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm. 2013;84(1):1-20.
  • Arias JL, Gallardo V, Ruiz MA, Delgado A. Eur J of Pharm Biopharm. 2008;69:54-63.
  • Pérez-Artacho B, Gallardo V, Ruiz MA, Arias JLJ. Nanopart Res. 2012;14:768.
  • Thiele H, von Levern HS. Synthetic protective colloids. J Colloid Sci. 1965;20(7):679-694.
  • Jagur-Grodzinski J. Biomedical application of functional polymers. React Funct Polym. 1999;39(2):99-138.
  • Lungwitz U, Breunig M, Blunk T, Göpferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005;60(2):247-266.
  • Intra J, Salem AK. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release. 2008;130(2):129-138.
  • Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliver Rev. 2002;54(5):715–758.
  • Brunner S, Fürtbauer E, Sauer T, Kursa M, Wagner E. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol Ther. 2002;5(1):80-86.
  • Xu DM, Yao SD, Liu YB at al. Size-dependent properties of M-PEIs nanogels for gene delivery in cancer cells. Int J Pharmaceut. 2007;338(1–2):291–296.
  • Fai VLC, Lee YD, Lee K, Lee KS, Ham DJ, Ju BK. Sensing properties of polyethylenimine coated carbon nanotubes in oxidized oil. Talanta. 2011;85 (1):463–468.
  • Suh J, Lee SH, Kim SM, Hah SS. Conformational Flexibility of Poly(ethylenimine) and Its Derivatives. Bioorg Chem. 1997;25(4):221–231.
  • Cao X, Li Z, Song X et al. Core-shell type multiarm star poly(ε-caprolactone) with high molecular weight hyperbranchedpolyethylenimine as core: Synthesis, characterization and encapsulation properties. Eur Polym J. 2008;44(4):1060–1070.
  • Lin C, Ge j. Multifunctional polyethylenimine-conjugated superparamagnetic nanoparticles for drug delivery and imaging. J Control Release. 2011;152(1):58-60.
  • Li N, Wang J, Yang X, Li L. Novel nanogels as drug delivery systems for poorly soluble anticancer drugs. Colloids Surf, B. 2011;83(2):237–244.
  • Thomas AM, Kapanen AI, Hare JI et al. Development of a liposomal nanoparticle formulation of 5-Fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacy. J Control Release. 2011; 150(2):212-219.
  • Qiu LY, Bae YH. Self-assembled polyethylenimine-graft-poly(ε-caprolactone) micelles as potential dual carriers of genes and anticancer drugs. Biomaterials. 2007;(28):4132–4142.
  • Gong P, Shi B, Zheng M et al. PEI protected aptamer molecular probes for contrast-enhanced in vivo cancer imaging. Biomaterials. 2012;33(31):7810-7817.
  • Yue Y, Jin F, Deng R, Cai J, Chen Y, Lin MC et al. Revisit complexation between DNA and polyethylenimine —effect of uncomplexed chains free in the solution mixture on gene transfection. J Control Release. 2011;155(1):67-76.
  • Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24(7):1121–1131.
  • Boussif O, Lezoualc’h F, Zanta MA ET al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Biochemistry-US. 1995; 92(16):7297-7301.
  • Masotti A, Moretti F, Mancini F et al. Physicochemical and biological study of selected hydrophobic polyethylenimine-based polycationic liposomes and their complexes with DNA. Bioorg medicinal chem. 2007;15(3):1504-1515.
  • Schäfer J, Höbel S, Bakowsky U, Aigner A. Liposome–polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010;31(26):6892-6900.
  • Rhaese S, von Briesen H, Rübsamen-Waigmann H, Kreuter J, Langer K. Human serum albumin–polyethylenimine nanoparticles for gene delivery. J Control Release. 2003;92:(1-2):199-208.
  • Lee SY, Huh MS, Lee S, Lee SJ, Chung H, Park J et al. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J Control Release. 2010;141(3):339-346.
  • Ikonen M, Murtomäki L, Kontturi K. Controlled complexation of plasmid DNA with cationic polymers: Effect of surfactant on the complexation and stability of the complexes. Colloids Surf, B: Biointerfaces. 2008;66(1):77-83.
  • Goula D, Benoist C, Mantero S, Merlo G, Levi G, Demeneix BA. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther.1998;5(9):1291-1295.
  • Wang T, Upponi J R, Torchilin V P. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharmaceut. 2012;427(1):3-20.
  • Huang S, Kamihira M. Development of hybrid viral vectors for gene therapy. Biotechnology Advances. 2013;31(2):208-223.
  • Wysocki PJ, Mackiewicz-Wysocka M, Mackiewicz A. Cancer gene therapy – state-of-the-art. Rep Prac Oncol Radiother. 2002;7(4):149-155.
  • Huh MS, Lee SY, Park S et al. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J Control Release. 2010;144(2):134–143.
  • Bivas-Benita M, Lin M Y, Bal S M et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA–PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine. 2009;2 (30):4010–4017.
  • Namgung R, Singha K, Yu MK et al. Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials. 2010;31(14):4204–4213.
  • Ferrari S, Pettenazzo A, Garbati N, Zacchello F, Behr J P, Scarpa M. Polyethylenimine shows properties of interest for cystic fibrosis gene therapy. BBA-Gene Struct Expr. 1999;1447(2–3):219–225.
  • Özgel G, Akbuğa J. In vitro characterization and transfection of IL-2 gene complexes. Int J Pharmaceut. 2006;315(1–2):44–51.
  • Springer C J, Niculescu-Duvaz I. Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs. Adv Drug Deliver Rev. 1996;22(3):351–364.
  • Liang B, He ML, Chan CY et al. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. Biomaterials. 2009;30(23–24):4014–4020.
  • Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hemat. 2001;39(1–2):155–171.
  • Li L, Yang J, Wang WW et al. Pigment epithelium-derived factor gene loaded in cRGD–PEG–PEI suppresses colorectal cancer growth by targeting endothelial cells. Int J Pharmaceut. 2012;438(1–2):1–10.
  • Liang B, He ML, Xiao ZP et al. Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene delivery. Biochem Bioph Res Co. 2008;367(4):874–880.
  • Neu M, Germershaus O, Behe M, Kissel T. Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo. J Control Release. 2007;124(1–2):69–80
Data source: Dialnet